Hisanori Shimizu
Overview
Explore the profile of Hisanori Shimizu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
40
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hashimoto K, Yokokawa T, Nonomiya Y, Shibata N, Soejima A, Kobayashi K, et al.
Oncology
. 2025 Mar;
:1-23.
PMID: 40064150
Introduction: Age has been reported as a risk factor for chemotherapy-induced nausea and vomiting. However, few reports have described risk factors for nausea and vomiting with carboplatin (CBDCA). This study...
2.
Yoshida N, Imai S, Kawakami K, Yokokawa T, Nakamura M, Aoyama T, et al.
J Cancer
. 2025 Feb;
16(5):1413-1419.
PMID: 39991570
Many studies have identified risk factors for neutropenia associated with various chemotherapies, including gemcitabine plus nab-paclitaxel (GnP). However, few studies have focused on the delayed recovery from neutropenia, which frequently...
3.
Iwasaki Y, Hiraide M, Taguchi H, Iehisa R, Akiyama H, Suzuki K, et al.
J Occup Environ Hyg
. 2024 Dec;
22(2):123-131.
PMID: 39656713
Hypochlorous acid (HClO), one of the major reactive oxygen species, is obtained by electrolyzing a sodium chloride solution. HClO is a safe and effective disinfectant and decomposing agent widely used...
4.
Asano M, Shimizu H, Yokokawa T, Suzuki W, Kawakami K, Kobayashi K, et al.
Gan To Kagaku Ryoho
. 2024 Oct;
51(9):913-918.
PMID: 39462626
Perioperative fluorouracil, epirubicin and cyclophosphamide(FEC)therapy is a standard treatment for breast cancer. However, more than 20% of patients with breast cancer who undergo FEC therapy experience febrile neutropenia(FN), for which...
5.
Tomomatsu T, Shimizu H, Yokokawa T, Fukada I, Kawakami K, Kobayashi K, et al.
Yakugaku Zasshi
. 2024 Sep;
144(9):897-904.
PMID: 39218657
This study aimed to estimate the medical costs associated with febrile neutropenia (FN) prophylaxis with pegfilgrastim and evaluate its impact on survival outcomes in daily practice in Japan. In this...
6.
Nonomiya Y, Nakayama I, Kobayashi K, Amakawa Y, Shibata N, Soejima A, et al.
Biol Pharm Bull
. 2024 Feb;
47(2):411-416.
PMID: 38346748
Trastuzumab deruxtecan (T-DXd) has displayed demonstrable efficacy and manageable toxicity in previously treated patients with advanced gastric and breast cancer, and it has been approved in Japan. However, there is...
7.
Kimura Y, Kawakami K, Nakamura M, Yokokawa T, Shimizu H, Kobayashi K, et al.
Yakugaku Zasshi
. 2023 Dec;
143(12):1075-1081.
PMID: 38044112
Since it is important that patients take their oral anticancer therapy as prescribed, pharmacists need to assess adherence. In addition, oral anticancer drugs are expensive, and reuse of leftover drugs...
8.
Tateai Y, Kawakami K, Teramae M, Fukuda N, Yokokawa T, Kobayashi K, et al.
PLoS One
. 2023 Nov;
18(11):e0294320.
PMID: 37972015
Background: Lenvatinib is an oral anticancer medication used to treat radioiodine-refractory thyroid cancer and unresectable hepatocellular carcinoma. The purpose of this study is to evaluate lenvatinib adherence by patients and...
9.
Hashimoto K, Kawakami K, Yokokawa T, Shibata N, Soejima A, Sugisaki T, et al.
Anticancer Res
. 2023 Sep;
43(10):4533-4541.
PMID: 37772578
Background/aim: Niraparib dosages can be individualized to reduce the starting dose based on body weight and baseline platelet count. However, even with individualized dosing, scattered cases of ≥Grade 3 hematologic...
10.
Ichimura T, Nomura H, Shimizu H
SAGE Open Med
. 2023 Apr;
11:20503121231164491.
PMID: 37026108
Objectives: Many patients with hormone-receptor positive breast cancer undergo prolonged treatment. However, the long-term patient quality of life assessment has not been examined. Using community pharmacists' assistance is one method...